Grazax (Phleum Pratense (225))

Grazax is indicated for the management of grass‑pollen–related allergic conditions.

• Seasonal allergic rhinitis (hay fever) caused by grass pollen.
• Allergic conjunctivitis triggered by grass pollen exposure.
• Prevention of symptom recurrence during the grass pollen season.
• Use as part of a comprehensive allergy management plan in patients with confirmed grass‑pollen sensitivity.

Side effects reported with sublingual grass pollen immunotherapy vary in frequency and severity.

Common

• Mild itching or irritation of the mouth or throat.
• Transient oral swelling or tingling sensation.
• Mild gastrointestinal discomfort such as nausea.
• Localized ear or nasal itching.

Serious

• Persistent or severe oral swelling that interferes with breathing.
• Anaphylactic reaction requiring emergency medical attention.
• Severe asthma exacerbation triggered by the tablet.

Before starting Grazax, certain precautions should be considered to ensure safe use.

• Confirmed diagnosis of grass‑pollen allergy by skin test or specific IgE.
• Not recommended for patients with uncontrolled asthma or severe respiratory disease.
• Use under medical supervision, especially during the first dose.
• Avoid if you have a history of severe allergic reactions to any component of the tablet.
• Discuss use during pregnancy or breastfeeding with a healthcare professional.
• Keep the tablet out of reach of children.

Grazax may interact with other medications or substances that affect the immune system or allergic response.

Avoid

• Concurrent use of other allergen immunotherapy products without medical guidance.
• Systemic corticosteroids at high doses during the treatment period.

Use with caution

• Beta‑agonist inhalers for asthma; monitor symptoms closely.
• Antihistamines may mask early signs of an allergic reaction.
• ACE inhibitors or NSAIDs if they have a known propensity to cause angio‑edema.